High-dose cyclophosphamide (HD-CTX) is largely employed in high-dose chemotherapy (HD-CHT) protocols. HD-CTX dose-limiting toxicity expresses itself as cardiac toxicity which is fatal in a minority of patients. The pathophysiology of HD-CTX-associated cardiotoxicity is still poorly understood. Autopsy studies in patients who died from acute HD-CTX-induced cardiac toxicity revealed hemorrhagic myocardial cell death and interstitial edema. Recently troponins, in particular troponin I (cTnI), have been found to represent a uniquely sensitive and specific marker of myocyte membrane integrity and therefore to increase in response to minimal myocardial cell damage in different settings, including doxorubicin-induced cardiotoxicity. We performed a multiparametric cardiologic monitoring in 16 consecutive breast cancer patients undergoing HD-CTX by means of serial ECG registrations and cardiac enzymes (CPK, CPK-MB and cTnI) determinations plus echocardiography in order to clarify acute cardiac events following HD-CTX administration. Neither overt cardiac toxicity nor cardiac enzymes elevation were recorded. Serial ECGs revealed in six cases little and reversible reduction of QRS voltage and/or ST abnormalities. Echo monitoring showed in four cases mild and transient increase of LV diastolic/systolic diameter/volume without decrease of FS% or EF% below normal values: in two of them abnormalities of diastolic function (E/A mitral doppler ratio) were also recorded. We conclude that our protocol of HD-CTX administration does not cause myocardial cell damage as analyzed by serum cTnI levels, thus suggesting that myocyte membrane injury may not be the first direct mechanism of HD-CTX cardiotoxicity. ECG (ie QRS voltages ) and Echo (ie E/A ratio) monitoring leads us to hypothesize that slight interstitial edema with reduction of LV diastolic compliance may be initial signs of cardiac dysfunction in this clinical setting. Bone Marrow Transplantation (2001) 28, 277-282.
High-dose cyclophosphamide (HD-CTX) is widely employed in transplant conditioning regimens as well as in sequential high-dose chemotherapy (HD-CHT) protocols for both solid and hematologic malignancies. The dose-limiting toxicity of CTX lies in its unique capability of causing an acute cardiomyopathy within 48 h of administration, presenting with tachycardia and refractory hypotension, which is often unresponsive to treatment. The risk of acute cardiotoxicity increases with the dose of CTX and becomes unacceptable for doses higher than 7 g/m 2 or 200 mg/kg, which are therefore considered the maximum tolerated dose. Although fulminant syndrome is rare, a significant proportion of patients receiving HD-CTX was shown to have instrumental (ie ECG and Echo) signs of cardiotoxicity even in the absence of clinical findings. [1] [2] [3] [4] The pathophysiology of HD-CTXinduced cardiomyopathy has not yet been fully elucidated. Autopsy studies showed that myocardial cell death takes place in a proportion of patients.
Recent clinical and experimental evidence identified troponin I (cTnI) as a most specific marker for myocardial cell damage. 5 It has been observed that this structural cell protein may be detected in the blood of patients with acute coronary syndrome, 6 after coronary angioplasty, 7 in heart failure, 8 acute myocarditis, 9 and other clinical situations in which conventional markers of myocyte necrosis are often negative. Thus, the new concept of 'minor myocardial damage' has emerged. Despite the lack of a satisfactory and univocal definition, this entity represents a substantially new field of research which allows the clinician to investigate for the presence of myocyte injury over a wide spectrum of pathologic conditions.
Based on these data, we performed a multiparametric assessment of cardiac function in patients treated with HD-CTX, testing for functional (Echo), electrical (ECG) and biochemical (cTnI, CPK and CPK-MB) abnormalities induced by this potentially cardiotoxic regimen.
Patients and methods

Patients' characteristics
Between March 1997 and April 1999, 16 consecutive female patients with histologically and/or cytologically demonstrated breast cancer, median age 41 years (range 34-58) were treated according to sequential HD-CHT with autologous hematopoietic progenitor cell support. The main characteristics of patients enrolled in this study are listed in Table 1 . Patients were high risk (Ͼ4 axillary nodes involved) primary breast cancer (n ϭ 8), inflammatory carcinoma (n ϭ 1), metastatic at presentation (n ϭ 1) or relapsed after conventional adjuvant chemotherapy stopped at least 3 months before entering the study (n ϭ 6). In this latter group of patients, one had received previous radiotherapy to the left thoracic wall and four had received previous anthracycline-containing chemotherapy. Eligibility criteria included age Ͻ60 years, normal bone marrow, cardiac, hepatic, pulmonary and renal function, negativity of HBsAg, anti-HCV and anti-HIV serologic tests. All patients underwent physical examination, 12-lead ECG and echocardiography by an attending cardiologist before entering the study. The following risk factors for cardiotoxicity were evaluated: age, sites of metastases (ie pericardium, pleura, chest wall), pertinent medical history (hypertension, coronary artery disease, diabetes mellitus, tobacco use), prior left thoracic wall radiotherapy, prior anthracycline exposure, and time interval between last dose of anthracycline and HD-CTX administration. of axillary nodes involved, followed by the reinfusion of autologous hematopoietic progenitor cells, as described elsewhere. 10 The treatment plan for metastatic disease was different in the epirubicin (150 mg/m 2 ) and melphalan (140 mg/m 2 ) dose and for the addition of a course of cisplatin 100 mg/m 2 day 1 plus etoposide 120 mg/m 2 days 1-3 between the second epirubicin cycle and the conditioning regimen (Figure 1 ).
Treatment plan
High-dose cyclophosphamide administration
High-dose cyclophosphamide (HD-CTX) was administered at the total dose of 7 g/m 2 divided in five separate 1-h infusions every 3 h over a 13-h period in conjunction with i.v. hydration, urine alkalinization and urothelial protection as described elsewhere.
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The dose of HD-CTX administered to this series of patients was calculated according to corrected ideal body weight ie ((actual Ϫ ideal) ϫ 25%) ϩ ideal, as suggested recently in order to reduce the risk of HD-CTX-induced cardiotoxicity in overweight patients. 10 This dose adjustment did not lead to patient undertreatment since the mean CTX dose administered was 163.5 mg/kg real body weight, which is comparable to the mean dose reported in the literature. 3 
Cardiac marker assay
Serum levels of cardiac troponin I and CPK-MB mass were determined by the Stratus II Fluorometric Enzyme Immunoassay (Dade, normal value Ͻ0.3 ng/ml and Ͻ5 ng/ml, respectively) while total CPK was measured on the Dimension UV Enzymatic Determination (DuPont, normal value Ͻ200 U/l). These markers were measured at baseline and 6, 12, 24 and 48 h after the first dose of HD-CTX.
cTnI was determined using a single antibody immunofluorescent test (Status II, Dade), with an intra-and interassay variability Ϯ0.1 ng/ml. Internal laboratory validation and large-scale studies 12 identified a threshold of 0.4 ng/ml as the minimum significant serum concentration of cTnI. In normal controls tested in our laboratory serum cTnI was constantly undetectable (ie ϭ 0).
ECG
A standard 12-lead ECG was obtained at baseline and 12, 24, 48 and 72 h after the first dose of HD-CTX. The following parameters were analyzed: heart rate and rhythm, QRS duration (QRSd), presence of ST abnormalities, QTc interval (corrected according to heart rate-Bazzett formula) and total QRS voltage (measured by summating the distance from the peak R wave height to the peak S wave trough in each of the six standard limb leads: these leads were chosen to minimize variability in QRS voltage due to lead placement). In particular, QTc interval and total QRS voltage were compared with baseline values and differences were expressed as percentage changes (Delta %).
Echocardiographic evaluation
A complete M-mode, 2D and color doppler echocardiogram were performed at baseline and 48-72 h after the first dose of HD-CTX in order to avoid transient fluid overload condition due to i.v. hydration. The following parameters were analyzed: M-mode end-diastolic diameter (EDD), end-systolic diameter (ESD), septum and posterior wall thickness, fractional shortening (FS%); 2D end-diastolic (EDV), endsystolic volume (ESV) and ejection fraction (EF%) were calculated according to modified 20-disks Simpson formula and corrected for body surface area. The E/A ratio of mitral doppler flow was analyzed as a marker for diastolic function. Pericardial effusion was recorded and measured, if present.
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Results
Clinical course
Baseline cardiac function was normal in all patients. Clinical evaluation including weighing; vital signs, cardiac and pulmonary evaluation were performed daily by the medical staff. None of the patients experienced clinical cardiotoxicity. Neither significant fluid retention and weight gain nor electrolyte imbalance were recorded. All patients were discharged from hospital on day 3 after HD-CTX administration. No clinical signs or symptoms of cardiotoxicity were recorded in any patient of this series after the end of the treatment protocol at a mean follow-up of 16 months (range 2-25 months).
Cardiac markers
Serial determinations of cardiac enzymes (CPK, CPK-MB and cTnI) did not exceed the threshold of normal values of our laboratory at any stage of sampling. In particular, cTnI was undetectable at baseline in all cases and remained undetectable after treatment in all but four cases (patients 3, 4, 14 and 15) in which cTnI was measurable but remained constantly below the accepted level of significance (0.1-0.3 ng/ml).
ECG
ECG baseline evaluation was normal in all but one patient (No. 3) who showed non-specific ST abnormalities. After treatment, no significant change was observed in heart rate, PR, QRSd and QTc intervals. QRS voltage showed a trend to a decrease, with a mean D of Ϫ7% (range 0-21%). A change Ͼ10% was observed in six patients (Nos 3, 5, 6, 7, 8 and 14) ( unchanged during the observation period, while in another four patients (Nos 2, 5, 9 and 15) they were detected from 6 to 72 h after the first dose of HD-CTX. In two cases ST abnormalities reverted after 48 h while in the other two they were still present at 72 h. Such ST abnormalities were otherwise unexplained. No complex atrial or ventricular arrhythmias were detected.
Echocardiographic measurements
Baseline echocardiographic parameters examined were in the normal range in all patients. In four out of 16 patients (Nos 3, 8, 10 and 11) we observed significant (more than two-fold interobserver variability of our laboratory) variation from baseline values of EDD, EDV and/or ESD and ESV. However, FS% and EF% never fell below 30% and 50%, respectively, in any patient (Table 2) . Doppler E/A mitral ratio showed significant change in two patients (Nos 3 and 14), from 1.2 to 0.8 in both, not related to fluid loading or pharmacological intervention nor heart rate variation, thus suggesting decreased left ventricular diastolic compliance. In one patient (No. 4) a mild pericardial effusion developed after HD-CTX administration and resolved at 3-month follow-up. In another patient (No. 2) suffering from mitral valve prolapse with mild regurgitation, a small pericardial effusion developed only at 1-month follow-up, after the second course of epirubicin.
Discussion
CTX plays a major role in therapy of breast cancer for metastatic disease as well as in the adjuvant setting. The steep dose-response effect 13 in conjunction with the powerful mobilization of hemopoietic progenitors 14 has made HD-CTX a part of almost all protocols of HDCT for breast cancer, 15, 16 as well as in hematological malignancies. Regimen-related toxicity refers to effects that can be directly attributed to the actual regimen used for conditioning patients for blood cell transplantation. A large number of chemotherapeutic agents are commonly used and most are administered in combination, making it sometimes difficult to identify the major determinant of toxicity. HDCTX doselimiting toxicity is represented by a unique acute and not dose-cumulative cardiomyopathy in patients receiving more than 100 mg/kg of CTX, usually arising within a 48 h period from administration and most often recorded in patients receiving more than 200 mg/kg administered as a bolus injection. 17 Age, previous anthracycline exposure and prior abnormal cardiac function are established risk factors. 18, 19 The importance of dose and rate of delivery, CTX and CTX metabolite plasma levels and plasma concentration-time curves (AUC), drug interactions along with patients' metabolic characteristics were recently identified as possible contributors to the syndrome. 2 Most patients treated with HD-CTX remain asymptomatic, some have mild symptoms of fluid retention, edema and tachypnea, while a few have an extremely fulminant course of cardiac failure (CHF) and shock that is resistant to intensive treatment and results in death.
The reported incidence of fatal HD-CTX-induced cardiotoxicity varies between 2 and 9.5%, depending on different regimens and the patient population.
1 Post-mortem examinations revealed hemorrhagic myocardial necrosis with interstitial edema, hemorrhage, and fibrin deposition, as well as vascular endothelial damage and pericardial effusion.
Acute CHF has been reported in 17 to 33% of patients receiving HD-CTX at a total dose of 170 to 180 mg/kg as once 4 or twice 3 daily dose or continuous infusion over a 4-day period as part of multi-drug conditioning regimens. 2 In addition, a significant proportion of asymptomatic patients showed instrumental (ECG, Echo) signs of cardiac impairment leading to the hypothesis that both interstitial edema (evidenced by reduced QRS voltage) and myocyte damage (revealed by systolic dysfunction) may take place following HD-CTX administration. 10 On the basis of clinical course, response to treatment and pathologic findings it has been suggested by a recent review that there may be other factors, ie peripheral vascular collapse, responsible for acute death besides pump failure. 1 In the past few years, troponins have emerged as specific and sensitive markers of myocardial cell damage in several settings, including chemotherapy-induced cardiotoxicity. Serial measurements of troponin T were performed in cancer patients undergoing left breast radiation therapy 20 or anthracycline-based chemotherapy in adults 21 and in children. 22 Very recently, cTnT serum levels from doxorubicindamaged myocytes of rats seemed to provide a sensitive tool for assessing the early cardiotoxicity of the drug 23 as well as in humans. 24, 25 The cardiac isoform of troponin I, which has been shown to be more specific than troponin T for myocardial injury, was utilized in order to detect anthracycline-associated damage in patients with hematologic malignancies 26 and to predict the development of cardiac dysfunction after multiple intermediate high-dose chemotherapy. 27 In the present study, we utilized cTnI in conjunction with ECG and Echo monitoring with the aim of defining the role, if any, of myocardial injury in the development of single-agent HD-CTX-induced cardiotoxicity.
In this series of breast cancer patients, neither acute clinical cardiotoxicity nor signs of myocardial cell necrosis, as revealed by cTnI increase, were recorded, even in patients who had received prior anthracycline-based chemotherapy or left breast radiotherapy or showed baseline cardiac abnormalities. ECG monitoring in 6/16 patients showed transient decreases in QRS voltage, 'electrical insulation', 4 and/or ST abnormalities. Echocardiography in 4/16 patients demonstrated significant but reversible increases of left ventricular diastolic/systolic dimensions or volumes with relative decrease of FS% and EF% but within the standard range of normality; in particular, only in two patients did we observe (transient) abnormal values of E/A mitral doppler ratio (abnormal relaxation-type).
The absence of minor myocardial damage and the finding that a minority of our patients receiving HD-CTX showed transient instrumental signs of cardiac function impairment provides further insight into the pathophysiology of HD-CTX-associated cardiotoxicity, suggesting that only endothelial damage associated with interstitial edema is likely to take place in these patients.
Compared to previous reports, 2, 4 in this study, singleagent HD-CTX was administered at an equivalent total dose but according to a single-day fractionated schedule.
The pharmacokinetic of HD-CTX plays an important role both in antitumor activity and organ toxicity. 2 Because of the prodrug nature of CTX and the extensive hepatic metabolism (cytochrome P450), these effects are related not only to the classical parameters of dose and AUC, but also to the bioactivated dose fraction and consequently to the enzymatic system of the metabolic pathway. This may in part account for the wide interpatient variability observed, and challenges the use of pharmacokinetic models that do not reflect exposure to activated metabolites. 31 also observed an inverse relationship between CTX and its metabolites, in patients receiving CTX after busulfan and/or phenitoin, and total body irradiation.
In the high-dose setting, CTX clearance may be influenced by several factors, including dose, administration rate, hydration, and drugs given before or concomitantly as supportive treatment or as a part of the induction regimen. [28] [29] [30] [31] Antibiotics, ranitidine dexamethasone (DEX), antiemetics (ondansetron, OND) are known to influence the CTX elimination pattern, accelerating (DEX, OND) CTX clearance and in some cases altering the efficacy/toxicity profile of the drug by an increase of patients' exposure to active metabolites. 32 CTX and thiotepa (TT), are frequently used simultaneously in high-dose chemotherapy regimens. Thiotepa is metabolized by cytochrome P450 (CYP2B and 2C families) to its main metabolite TEPA. The CYP2C family is also involved in the 4-hydroxylation of CTX. 33 A striking sequence dependency of CTX pharmacokinetics was observed when TT was administered prior to CTX resulting in a strong inhibition of CTX bioactivation leading to a possible reduction of antitumor and toxic effects. 34 It has been demonstrated in preclinical models that administration of repeated doses of CTX results in lower toxicity and greater therapeutic efficacy than an equal total dose given as a single bolus. 35 Our results and larger clinical studies 10, 36 confirm that this schedule of administration is safe as far as cardiotoxicity is concerned.
These data support the hypothesis originally proposed by Ayash et al, 2 who suggested that a spectrum of HD-CTXassociated cardiotoxicity exists, ranging from asymptomatic transient cardiac function impairment to an irreversible cardiomyopathy, mainly as a function of dose, schedule and enhanced cyclophosphamide activation possibly related to concurrent drug administration.
